"The most fruitful basis of the discovery of a new drug is to start with an old drug" is a quote provided by the Nobel Laureate, and renowned pharmacologist James Black who endorsed that drug repurposing is very much a viable strategy for successful drug discovery and development.
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old&' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates 
Drug repurposing (DR) or drug repositioning involves identification of new therapeutic use(s) for old/existing/available. This is the process of uncovering new indications of the approved or failed/abandoned compounds for use in a different disease. This process involves a strategy to identify advanced uses for preapproved drugs or existing medications. The basic idea of repurposing is to discover new useful activity for a distinct malady in an older clinically used drug or one that failed in later stages of development . This has emerged as an effective strategy in discovering or developing drug molecules with new pharmacological/therapeutic indications .
DRUG REPURPOSING CAPABILITY AT DRF
Repurposing existing drugs can help find outbreak treatments against the clock. We at DRF have a unique and extensive repertoire of in vitro and in vivo functional screening assays in multiple therapeutic areas such as Oncology, Immunity, inflammation, metabolic disorders, dermatology, covid etc.
This can be efficiently utilized for the objective of drug repurposing based on following key points:
The detailed information on our range of preclinical models can be accessed at following link: https://www.daburresearch.in